154 related articles for article (PubMed ID: 31478942)
1. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
[TBL] [Abstract][Full Text] [Related]
2. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
[TBL] [Abstract][Full Text] [Related]
4. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
5. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.
Hoang LN; Ali RH; Lau S; Gilks CB; Lee CH
Int J Gynecol Pathol; 2014 Sep; 33(5):483-91. PubMed ID: 25083964
[TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
9. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
10. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
[TBL] [Abstract][Full Text] [Related]
11. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
13. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
14. Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma.
Saharti SN; Altaf FJ
Saudi Med J; 2024 Jun; 45(6):560-564. PubMed ID: 38830650
[TBL] [Abstract][Full Text] [Related]
15. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
[No Abstract] [Full Text] [Related]
17. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
Weisman P; Park KJ; Xu J
Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
[TBL] [Abstract][Full Text] [Related]
18. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
20. The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.
Olcha P; Cybulski M; Skomra D; Obrzut B; Ignatov A; Jóźwik M; Schneider-Stock R; Semczuk A
Int J Gynecol Cancer; 2010 Aug; 20(6):993-9. PubMed ID: 20683407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
